Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

October 9, 2018

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

July 18, 2018

Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers

April 24, 2018

REVOLUTION Medicines Raises $56 Million Series B Financing

October 5, 2017

REVOLUTION Medicines Appoints Vincent Miller, M.D. to Board of Directors

September 14, 2017

Revolution Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations

March 20, 2017

REVOLUTION Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development

December 20, 2016

REVOLUTION Medicines Raises Additional $25 Million in Series A Financing

December 13, 2016

REVOLUTION Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles

June 14, 2016

REVOLUTION Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., and Senior Advisor, Eric Gordon, Ph.D.

September 30, 2015

FierceBiotech Names Revolution Medicines as a “Fierce 15” Biotech Company of 2015

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Next page
Last page

Displaying 31 - 40 of 45

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2020 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations